Ki-67 and Bax expression in esophageal mucosa might have implications in ablative therapies for Barrett’s esophagus, dysplasia, and adenocarcinoma-Reference-Cited by-同舟云学术

Ki-67 and Bax expression in esophageal mucosa might have implications in ablative therapies for Barrett’s esophagus, dysplasia, and adenocarcinoma

Published:2011-08-20 Issue:1 Volume:26 Page:283-284
ISSN:0930-2794
Container-title:Surgical Endoscopy
language:en
Short-container-title:Surg Endosc

Author:

Kountouras Jannis,Chatzopoulos Dimitrios,Zavos Christos,Deretzi Georgia,Polyzos Stergios A.,Gavalas Emmanuel,Klonizakis Philippos,Vardaka Elizabeth,Katsinelos Panagiotis,Stergiopoulos Christos,Moschos John,Giartza-Taxidou Evaggelia

Publisher

Springer Science and Business Media LLC

Subject

Surgery

Link

http://link.springer.com/content/pdf/10.1007/s00464-011-1864-1.pdf

Reference14 articles.

1. Lewis CJ, Thrumurthy SG, Pritchard S, Armstrong G, Attwood SE (2011) Comparison of COX-2, Ki-67, and BCL-2 expression in normal esophageal mucosa, Barrett’s esophagus, dysplasia, and adenocarcinoma with postablation mucosa and implications for ablative therapies. Surg Endosc 25:2564–2569

2. Pera M, Manterola C, Vidal O, Grande L (2005) Epidemiology of esophageal adenocarcinoma. J Surg Oncol 92:151–159

3. Voutilainen ME, Juhola MT (2005) The changing epidemiology of esophageal cancer in Finland and the impact of the surveillance of Barrett’s esophagus in detecting esophageal adenocarcinoma. Dis Esophagus 18:221–225

4. Garidou A, Tzonou A, Lipworth L, Signorello LB, Kalapothaki V, Trichopoulos D (1996) Life-style factors and medical conditions in relation to esophageal cancer by histologic type in a low-risk population. Int J Cancer 68:295–299

5. Garidou A, Tzonou A, Lipworth L, Signorello LB, Kalapothaki V, Trichopoulos D (1996) Diet and risk of esophageal cancer by histologic type in a low-risk population. Int J Cancer 68:300–304